Dr. Sofia Sousa is a post-doctoral researcher at the Department of Experimental Medicine at Dana-Farber Cancer Institute (DFCI), Harvard Medical School. Dr. Sousa received her Ph.D., from the University of Eastern Finland under a Marie-Curie European Initial Training Network (2015), and her MSc (2009) and BSc (2008) from the Faculty of Pharmacy, University of Porto. During her PhD, she studied the role of tumor-associated macrophages (TAM) in breast cancer bone metastasis and the feasibility of TAM targeting strategies for metastasis prevention. Her research focus has since broadened, to the targeting of other bone microenvironmental cells and processes as a post-doctoral researcher in the group of Professor Clezardin at the University of Lyon (2016-2018). The importance of inter-individual immunological differences in the pathogenesis of cancer and other pathologies and the belief that the immune system is a source of disease response variability and a key aspect that should be harnessed into biomarker and personalized therapy development brought her to her current position. In Dr. Eva Guinan’s lab, at DFCI, Dr. Sousa’s research focuses on the use of ex vivo generated regulatory T cells for adoptive transfer to patients in different transplant and immunological imbalance settings.